COMP <GO>
ICCC vs MRK // PIOTROSKI F-SCORE QUALITY
ImmuCell Corporation (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ICCC 3
— MRK 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: ICCC
LAST: $10.26 (-0.58%) • MKT CAP: $93.7M
piotroski-score
8/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICCC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICCC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.40% | 74.80% | -33.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.20% | 20.70% | -16.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.9x | 15.3x | +20.60 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.31% | 3.42% | -2.11 | MRK | /fcf-yield <GO> |
| Operating Margin | 6.00% | 34.30% | -28.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -3.80% | 28.10% | -31.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 1.30% | +3.00 | ICCC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.28 | 5.19 | -0.91 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.8 | 51.7 | +0.10 | ICCC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $93.7M | $361.02B | -$360.93B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICCC REV | MRK REV | ICCC GROSS % | MRK GROSS % | ICCC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.6M | $65.01B | 41.4% | 74.8% | $1.2M | $12.36B |
| FY 2024 | $26.5M | $64.17B | 30.0% | 76.3% | -$107.8K | $18.10B |
| FY 2023 | $17.5M | $60.12B | — | — | -$4.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICCC // BETA —
MRK // BETA 0.92